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The authors regret that incorrect data was published within the ‘Evaluating Clinical Response’ section, para 2 on page 1106.
The correct data is printed below.
In responders, annualized rates of clinically significant exacerbations were reduced by 60% (0.73 vs 1.84, P < 0.0001 vs
placebo), severe exacerbations by 76% (0.24 vs 1.00, P < 0.0001 vs placebo) and total emergency visits by 76% (0.18 vs 0.77,
P < 0.0001 vs placebo) (Novartis, data on file).DOI of original article: 10.1016/j.rmed.2009.03.008.
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